BRCA1 and neoplasm: By contrast, in platinum-resistant HGSOC, the combination of bevacizumab, olaparib, and durvalumab was associated with a worse 3-month PFS for patients with BRCA1/2-mutant tumours compared to those with BRCA1/2-wildtype tumours (50.0% [90% CI, 10.3–80.9] vs 72.2% [90% CI, 57.8–82.4]); in line with this finding, patients who had previously received PARPi had a lower PFS, thereby suggesting a role for acquired resistance to PARPi in the worse outcome of this patient population, despite the triple combination therapy.